{
  "docId": "019de071-f648-72d0-9c84-3373768bf908",
  "docSlug": "15eb2f0f83943ed61260bacd75adb779",
  "documentTitle": "ATAI | Investor Day Presentation Deck | 42 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 42,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide contrasts specific receptor-targeted programs with a more complex multi-receptor approach.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-f648-72d0-9c84-3373768bf908/17",
  "deckHref": "/decks/019de071-f648-72d0-9c84-3373768bf908",
  "deckJsonHref": "/decks/019de071-f648-72d0-9c84-3373768bf908.json",
  "deckAnchorHref": "/decks/019de071-f648-72d0-9c84-3373768bf908#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.9,
        "x": 0.04,
        "y": 0.15
      },
      "kind": "list",
      "text": "Cognition as a Primary Endpoint: Boehringer Ingelheim GlyT1 inhibitor; Biogen AMPA receptor modulator; Neurocrine/Takeda Luvadaxistat (with mixed outcomes).",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "adf54631-602e-44ac-81c8-3820c96fa3ac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.5,
        "x": 0.04,
        "y": 0.65
      },
      "kind": "list",
      "text": "Cognition as Secondary Endpoint: Several studies but cognition not listed on clinicaltrials.gov",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f3777359-04e3-4afa-a602-55bf74dc705c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.92,
        "x": 0.04,
        "y": 0.8
      },
      "kind": "paragraph",
      "text": "Note that many of these programs have specific mechanisms of action while the Recognify compound has a more complex MoA that modulates multiple receptor systems. Other compounds that target multiple receptor systems, such as clozapine, have demonstrated powerful efficacy in schizophrenia.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c824a1bd-4282-4fef-9009-cd20551b9bce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.55,
        "x": 0.035,
        "y": 0.035
      },
      "kind": "title",
      "text": "Key Phase 2 and 3 CIAS Programs in Progress",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a98084e-064a-419e-8707-8e39e4f1c40b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}